Barclays Maintains Overweight on Omada Health, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 78.4%

Neg 0% Neu 0% Pos 78.4%

Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and raises the price target from $25 to $27.